(GTBP) – StreetInsider.com Reports
-
GT Biopharma, Inc. (GTBP) Tops Q3 EPS by 3c
-
Peter Derycz and Bristol Investment Fund Ltd. Issue Open Letter Research Solutions (RSSS)
-
GT Biopharma, Inc. (GTBP) Tops Q1 EPS by 16c
-
GT Biopharma (GTBP) Appoints Charles J. Casamento to its Board
-
GT Biopharma (GTBP) Issues Open Letter to Shareholders Detailing Recent Activities
-
EF Hutton Starts GT Biopharma Inc. (GTBP) at Hold
-
GT Biopharma (GTBP) Prices 6.5M Share Direct Offering at $1/sh
-
GT Biopharma (GTBP) Names Dr. Jeff Miller as Consulting Chief Medical Officer
-
GT Biopharma (GTBP) and Fate Therapeutics (FATE) Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
-
GT Biopharma (GTBP) Reports Q3, Provides Business Update
-
GT Biopharma (GTBP) Announces Proposed $150M Share and Warrant Offering
-
GT Biopharma Inc. (GTBP) PT Lowered to $5 at H.C. Wainwright
-
GT Biopharma (GTBP) Affirms Manufacturing Timeline For GTB-3650
-
Roth Capital Downgrades GT Biopharma Inc. (GTBP) to Neutral
-
GT Biopharma (GTBP) Reports Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager Driving Robust NK Cell Function Against B Cell Malignancies
-
GT Biopharma (GTBP) Reports Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas
-
GT Biopharma (GTBP) Presents TriKE Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data
-
GT Biopharma (GTBP) Presents Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer
-
GT Biopharma (GTBP) Appoints Manu Ohri as CFO
-
GT Biopharma Inc. (GTBP) PT Lowered to $18 at B.Riley
-
GT Biopharma (GTBP) Shows Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
-
GT Biopharma (GTBP) Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO
-
GT Biopharma (GTBP) Receives $16M of Warrant Exercise Proceeds
-
GT Biopharma Inc. (GTBP) PT Raised to $26 at B.Riley
-
UPDATE: H.C. Wainwright Starts GT Biopharma Inc. (GTBP) at Buy
-
GT Biopharma (GTBP) Announces Update On Commencement Of GTB-3550 TriKE Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE Product Candidates
-
Companies with NDRs 4/15
-
Companies with NDRs 4/14
-
Companies with NDRs 4/13
-
B.Riley Starts GT Biopharma Inc. (GTBP) at Buy
-
GT Biopharma (GTBP) Enrolls Patient 10 in GTB-3550 TriKE Phase I/II Clinical Trial
-
GT Biopharma (GTBP) Announces Updated Interim GTB-3550 Trike Clinical Trial Results
-
UPDATE: Roth Capital Starts GT Biopharma Inc. (GTBP) at Buy
-
GT Biopharma (GTBP) Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer
-
GT Biopharma, Inc. (GTBP) Reports Elimination of HIV Infected Cells Using Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing
-
GT Biopharma Inc. (GTBP) Granted FDA Clearance for First-in-Human Phase 1 Study of First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550
-
GT Biopharma Inc. (GTBP) Reports Postive Results For Two Next Generation Trikes In Solid Tumors
-
GT Biopharma (GTBP) Reports Update to OXS-3550 IND Filing
Back to GTBP Stock Lookup
